NCT06532591View on ClinicalTrials.gov

Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

October 1, 2025

Conditions

NSCLC

Interventions

DRUG

cadonilimab+paclitaxel/albumin-bound paclitaxel+carboplatin

PD-1/CTLA-4 bispecific antibody，Cadonilimab 10mg/kg IV, q3w, paclitaxel 175mg/m2 or albumin-bound paclitaxel 260mg/m2 ivgtt d1, q3w carboplatin AUC 5 ivgtt d1, q3w

Trial Locations (1)

610000

RECRUITING

Sichuan Provincial Tumor Hospital, Chengdu

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER